Trial reportDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2015
Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial.
Trial report in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 6 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Translational medications development for methamphetamine use disorder: A systematic review of preclinical, human laboratory, and clinical research.Pharmacological reviews · 2026Pooled it
- Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis.Psychopharmacology · 2020Pooled it
- Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review.CNS drugs · 2020Pooled it
- Treatment of amphetamine abuse/use disorder: a systematic review of a recent health concern.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2019Pooled it
- Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis.Systematic reviews · 2016Pooled it
- The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder.Journal of addiction medicineGuideline
- Ifenprodil for the treatment of methamphetamine use disorder: An exploratory, randomized, double-blind, placebo-controlled trial.Neuropsychopharmacology reports · 2022Trial
- Trial
- Prescription psychostimulants or atomoxetine and the risk of stimulant-related hospital admissions in adults with and without stimulant use disorder: a Swedish population-based within-individual observational study.The Lancet regional health. Europe · 2026Article
- Perceptions of prospective pharmaceutical stimulant substitution treatments among people who use illicit stimulants in Vancouver, Canada.The International journal on drug policy · 2024Article
- Methamphetamine Toxicities and Clinical Management.NEJM evidence · 2023 · on this mapReview
- Methylphenidate as a treatment option for substance use disorder: a transdiagnostic perspective.Frontiers in psychiatry · 2023Article
- Goofballing of Opioid and Methamphetamine: The Science Behind the Deadly Cocktail.Frontiers in pharmacology · 2022Review
- Effects of the GluN2B-selective antagonist Ro 63-1908 on acquisition and expression of methamphetamine conditioned place preference in male and female rats.Drug and alcohol dependence · 2021Article
- The therapeutic effects of methylphenidate and matrix-methylphenidate on addiction severity, craving, relapse and mental health in the methamphetamine use disorder.Substance abuse treatment, prevention, and policy · 2020Article
- Stimulant safe supply: a potential opportunity to respond to the overdose epidemic.Harm reduction journal · 2020Review
- Adding extended-release methylphenidate to psychological intervention for treatment of methamphetamine dependence: A double-blind randomized controlled trial.Medical journal of the Islamic Republic of Iran · 2020Article
- Effects of Modafinil on Sleep Pattern during Methamphetamine Withdrawal: A Double-blind Randomized Controlled Trial.Addiction & health · 2019Article
- Study of effects of ifenprodil in patients with methamphetamine dependence: Protocol for an exploratory, randomized, double-blind, placebo-controlled trial.Neuropsychopharmacology reports · 2019Article
- The neurobiological mechanisms of physical exercise in methamphetamine addiction.CNS neuroscience & therapeutics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe objective of this randomized, double-blind, placebo-controlled study was to evaluate the efficacy of sustained-release methylphenidate (MPH-SR) in treatment of methamphetamine dependence.
methodsFifty-six individuals who met DSM-IV-TR criteria for methamphetamine dependence participated in this 10-week trial. The participants were randomly allocated into two groups and received 18 to 54 mg/day sustained-released methylphenidate or placebo for 10 weeks. Craving was evaluated by a visual analogue craving scale every week. Urinary screening test for methamphetamine was carried out each week. The Beck Depression Inventory-II (BDI-II) was used to monitor participant depressive symptoms at baseline and bi-weekly during the treatment period.
resultsAt the end of the trial, the MPH-SR group was less methamphetamine positive compared to the placebo group and the difference was significant (p = 0.03). By the end of the study, MPH-SR group showed significantly less craving scores compared to the placebo group [MD (95% CI) = -10.28(0.88-19.18), t(54) = 2.19, p = 0.03]. There was greater improvement in the depressive symptoms scores in the intervention group compared to the placebo group [MD (95% CI) =2.03(0.31-3.75), t (54) =2.37, p = 0.02].
conclusionSustained-released methylphenidate was safe and well tolerated among active methamphetamine users and significantly reduced methamphetamine use, craving and depressive symptoms.
trial registrationIRCT201202281556N38.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.